Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $23.00 at Royal Bank Of Canada

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its target price reduced by equities research analysts at Royal Bank Of Canada from $25.00 to $23.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a "sector perform" rating on the biotechnology company's stock. Royal Bank Of Canada's target price indicates a potential upside of 4.69% from the stock's previous close.

A number of other equities research analysts have also recently commented on the stock. Morgan Stanley reissued an "equal weight" rating and set a $40.00 target price (down previously from $113.00) on shares of Sarepta Therapeutics in a research report on Monday, June 16th. Jefferies Financial Group cut their price target on shares of Sarepta Therapeutics from $125.00 to $54.00 and set a "buy" rating on the stock in a research note on Monday, June 16th. Robert W. Baird increased their price objective on shares of Sarepta Therapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a research note on Thursday. Needham & Company LLC reissued a "buy" rating and set a $50.00 price target on shares of Sarepta Therapeutics in a report on Thursday. Finally, Scotiabank raised shares of Sarepta Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $80.00 price target on the stock in a report on Friday, June 6th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $57.00.

Sarepta Therapeutics Trading Up 19.5%

Sarepta Therapeutics stock traded up $3.59 during trading hours on Thursday, hitting $21.97. The company had a trading volume of 19,698,423 shares, compared to its average volume of 2,388,922. The firm has a market cap of $2.16 billion, a P/E ratio of -8.17 and a beta of 0.45. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.46 and a current ratio of 4.02. Sarepta Therapeutics has a 1 year low of $16.88 and a 1 year high of $150.48. The company has a 50-day moving average price of $28.86 and a two-hundred day moving average price of $69.08.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The business had revenue of $744.86 million during the quarter, compared to analysts' expectations of $685.75 million. During the same period in the previous year, the company posted $0.73 EPS. Sarepta Therapeutics's revenue for the quarter was up 80.2% on a year-over-year basis. On average, sell-side analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. increased its position in shares of Sarepta Therapeutics by 5.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company's stock valued at $352,000 after acquiring an additional 145 shares during the last quarter. Commonwealth Equity Services LLC grew its holdings in Sarepta Therapeutics by 22.1% during the 4th quarter. Commonwealth Equity Services LLC now owns 6,357 shares of the biotechnology company's stock worth $773,000 after acquiring an additional 1,151 shares in the last quarter. Corient Private Wealth LLC acquired a new position in Sarepta Therapeutics during the 4th quarter worth approximately $786,000. Xponance Inc. lifted its position in shares of Sarepta Therapeutics by 3.1% during the 4th quarter. Xponance Inc. now owns 18,713 shares of the biotechnology company's stock worth $2,275,000 after buying an additional 571 shares during the last quarter. Finally, Teacher Retirement System of Texas boosted its holdings in shares of Sarepta Therapeutics by 19.1% in the 4th quarter. Teacher Retirement System of Texas now owns 25,412 shares of the biotechnology company's stock valued at $3,090,000 after buying an additional 4,076 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.